Shopping Cart 0
Cart Subtotal
USD 0

Uveitis - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Uveitis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis-Pipeline Review, H2 2018, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 8, 6, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Uveitis-Overview 6

Uveitis-Therapeutics Development 7

Uveitis-Therapeutics Assessment 17

Uveitis-Companies Involved in Therapeutics Development 25

Uveitis-Drug Profiles 40

Uveitis-Dormant Projects 177

Uveitis-Discontinued Products 181

Uveitis-Product Development Milestones 182

Appendix 200


List Of Figure

List of Figures

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Uveitis-Pipeline by Aciont Inc, H2 2018

Uveitis-Pipeline by Aldeyra Therapeutics Inc, H2 2018

Uveitis-Pipeline by Alvotech Iceland, H2 2018

Uveitis-Pipeline by Apitope International NV, H2 2018

Uveitis-Pipeline by Bristol-Myers Squibb Co, H2 2018

Uveitis-Pipeline by Clearside BioMedical Inc, H2 2018

Uveitis-Pipeline by Coherus BioSciences Inc, H2 2018

Uveitis-Pipeline by Elasmogen Ltd, H2 2018

Uveitis-Pipeline by Enzo Biochem Inc, H2 2018

Uveitis-Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Uveitis-Pipeline by EyePoint Pharmaceuticals Inc, H2 2018

Uveitis-Pipeline by Eyevensys SAS, H2 2018

Uveitis-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Uveitis-Pipeline by Fresenius SE & Co KGaA, H2 2018

Uveitis-Pipeline by Galapagos NV, H2 2018

Uveitis-Pipeline by HanAll Biopharma Co Ltd, H2 2018

Uveitis-Pipeline by Idera Pharmaceuticals Inc, H2 2018

Uveitis-Pipeline by Johnson & Johnson, H2 2018

Uveitis-Pipeline by Kv1.3 Therapeutics, H2 2018

Uveitis-Pipeline by Midatech Pharma Plc, H2 2018

Uveitis-Pipeline by Mitotech SA, H2 2018

Uveitis-Pipeline by Nemus Bioscience Inc, H2 2018

Uveitis-Pipeline by Novartis AG, H2 2018

Uveitis-Pipeline by OncoNOx ApS, H2 2018

Uveitis-Pipeline by Ophthotech Corp, H2 2018

Uveitis-Pipeline by Orchid Pharma Ltd, H2 2018

Uveitis-Pipeline by Palatin Technologies Inc, H2 2018

Uveitis-Pipeline by Panoptes Pharma GesmbH, H2 2018

Uveitis-Pipeline by Re-Pharm Ltd, H2 2018

Uveitis-Pipeline by Sandoz International GmbH, H2 2018

Uveitis-Pipeline by Santen Pharmaceutical Co Ltd, H2 2018

Uveitis-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Uveitis-Dormant Projects, H2 2018

Uveitis-Dormant Projects, H2 2018 (Contd..1), H2 2018

Uveitis-Dormant Projects, H2 2018 (Contd..2), H2 2018

Uveitis-Dormant Projects, H2 2018 (Contd..3), H2 2018

Uveitis-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Uveitis Therapeutic Products under Development, Key Players in Uveitis Therapeutics, Uveitis Pipeline Overview, Uveitis Pipeline, Uveitis Pipeline Assessment


Companies

Aciont Inc

Aldeyra Therapeutics Inc

Alvotech Iceland

Apitope International NV

Bristol-Myers Squibb Co

Clearside BioMedical Inc

Coherus BioSciences Inc

Elasmogen Ltd

Enzo Biochem Inc

EyeGate Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

Fresenius SE & Co KGaA

Galapagos NV

HanAll Biopharma Co Ltd

Idera Pharmaceuticals Inc

Johnson & Johnson

Kv1.3 Therapeutics

Midatech Pharma Plc

Mitotech SA

Nemus Bioscience Inc

Novartis AG

OncoNOx ApS

Ophthotech Corp

Orchid Pharma Ltd

Palatin Technologies Inc

Panoptes Pharma GesmbH

Re-Pharm Ltd

Sandoz International GmbH

Santen Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd